Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled dose-ranging study of MEDI2070 in anti-TNF-experienced Crohn's disease
NL-OMON46166Phase 2Active, not recruiting
- Sponsor
- Allergan
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of brazikumab in Crohn's disease, sponsored by Allergan. Started Mar 2017; status: active, not recruiting.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON46166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46166.